Long-term clinical outcomes and genomic predictors of PSMA-PET/CT-guided cytoreductive progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer. Radium 223 ...
Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...
Mechanism of action. The efficacy of a GnRH agonist in the treatment of PMS depends on its ability to cause pituitary desensitization to GnRH. Depending on the potency of the agonist, the ...
Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...
Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule ...
The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results